TITLE

The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

AUTHOR(S)
Mallinckrodt, Craig H.; Raskin, Joel; Wohlreich, Madelaine M.; Watkin, John G.; Detke, Michael J.
PUB. DATE
January 2004
SOURCE
BMC Psychiatry;2004, Vol. 4, p26
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A mixed-effects model repeated measures approach (MMRM) was specified as the primary analysis in the Phase III clinical trials of duloxetine for the treatment of major depressive disorder (MDD). Analysis of covariance using the last observation carried forward approach to impute missing values (LOCF_ANCOVA) was specified as a secondary analysis. Previous research has shown that MMRM and LOCF_ANCOVA yield identical endpoint results when no data are missing, while MMRM is more robust to biases from missing data and thereby provides superior control of Type I and Type II error compared with LOCF_ANCOVA. We compared results from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how the choice of primary analysis may influence interpretations of efficacy. Methods: Results were obtained from the eight acute-phase clinical trials that formed the basis of duloxetine's New Drug Application for the treatment of MDD. All 202 mean change analyses from the 20 rating scale total scores and subscales specified a priori in the various protocols were included in the comparisons. Results: In 166/202 comparisons (82.2%), MMRM and LOCF_ANCOVA agreed with regard to the statistical significance of the differences between duloxetine and placebo. In 25/202 cases (12.4%), MMRM yielded a significant difference when LOCF_ANCOVA did not, while in 11/202 cases (5.4%), LOCF_ANCOVA produced a significant difference when MMRM did not. In 110/202 comparisons (54.4%) the p-value from MMRM was lower than that from LOCF_ANCOVA, while in 69/202 comparisons (34.2%), the p-value from LOCF_ANCOVA was lower than that from MMRM. In the remaining 23 comparisons (11.4%), the p-values from LOCF_ANCOVA and MMRM were equal when rounded to the 3rd decimal place (usually as a result of both p-values being < .001). For the HAMD17 total score, the primary outcome in all studies, MMRM yielded 9/12 (75%) significant contrasts, compared with 6/12 (50%) for LOCF_ANCOVA. The expected success rate was 80%. Conclusions: Important differences exist between MMRM and LOCF_ANCOVA. Empirical research has clearly demonstrated the theoretical advantages of MMRM over LOCF_ANCOVA. However, interpretations regarding the efficacy of duloxetine in MDD were unaffected by the choice of analytical technique.
ACCESSION #
29323667

 

Related Articles

  • A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. Keller, Martin B.; McCullough, James P.; Klein, Daniel N.; Arnow, Bruce; Dunner, David L.; Gelenberg, Alan J.; Markowitz, John C.; Nemeroff, Charles B.; Russell, James M.; Thase, Michael E.; Trivedi, Madhukar H.; Blalock, Janice A.; Borian, Frances E.; Jody, Darlene N.; DeBattista, Charles; Koran, Lorrin M.; Schatzberg, Alan F.; Fawcett, Jan; Hirschfeld, Robert M.A.; Keitner, Gabor // New England Journal of Medicine;05/18/2000, Vol. 342 Issue 20, p1462 

    Background: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with...

  • Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Blackburn, I.-M.; Moore, R. G. // British Journal of Psychiatry;Oct97, Vol. 171, p328 

    Background: We report a randomised controlled trial, in both the acute and maintenance stage of treatment, in 75 out-patients with recurrent major depression.Method: Patients were allocated to three groups: 16 weeks of acute treatment and two years' maintenance...

  • Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Thase, Michael E.; Larsen, Klaus G.; Kennedy, Sidney H. // British Journal of Psychiatry;Dec2011, Vol. 199 Issue 6, p501 

    Background: There is controversy about the implications of relatively small average drug-placebo differences observed in randomised controlled trials of antidepressant medications.Aims: To investigate whether efficacy is better understood as a large effect in a subgroup...

  • 2009 - Review: Differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression. Usherwood, Tim // ACP Journal Club;7/21/2009, Vol. 151 Issue 1, p8 

    The article focuses on a study of the relative efficacy of 12 new-generation antidepressants for relieving major depression. The study was conducted through randomized controlled trials (RCTs). The study concluded that new-generation antidepressants differ in efficacy and acceptability in...

  • Medication Augmentation after the Failure of SSRIs for Depression. Trivedi, Madhukar H.; Fava, Maurizio; Wisniewski, Stephen R.; Thase, Michael E.; Quitkin, Frederick; Warden, Diane; Ritz, Louise; Nierenberg, Andrew A.; Lebowitz, Barry D.; Biggs, Melanie M.; Luther, James F.; Shores-Wilson, Kathy; Rush, A. John // New England Journal of Medicine;3/23/2006, Vol. 354 Issue 12, p1243 

    Background: Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach. Methods: We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without...

  • Leki zioÅ‚owe w leczeniu depresji -- aktualny stan wiedzy. Szafrański, Tomasz // Psychiatria Polska;2014, Vol. 48 Issue 1, p59 

    Recent decades have seen development of research and an increased interest in the psychopharmacology of natural remedies. More than 20 herbal remedies have been identified that may potentially be applied in medicine as antidepressive, anxiety relieving or sleep-inducing agents. Patients often...

  • Response to tricyclic antidepressants: independent of gender?  // Current Medical Literature: Psychiatry;2004, Vol. 15 Issue 2, p40 

    Discusses research being done on gender differences in etiology and pathogenesis of depression. Reference to a study by T. Wohlfarth, J. G. Storosum, A. J. Elferink, B. J. Van Zwieten, A. Fouwels and W. Van Den Brink, published in the 2004 issue of the "American Journal of Psychiatry";...

  • Antidepressant Combinations: Widely Used, But Far From Empirically Validated. Thase, Michael E. // Canadian Journal of Psychiatry;Jun2011, Vol. 56 Issue 6, p317 

    This paper reviews the evidence on combining antidepressants (ADs) for treatment of major depressive disorder. Although widely used and usually safe, the efficacy of even the most widely prescribed combinations of ADs has not been established by properly controlled, adequately powered, clinical...

  • Intervenciones psicol�gicas y farmacol�gicas para dejar de fumar en fumadores con un trastorno depresivo. V�ZQUEZ, FERNANDO L. // Clinica y Salud;2005, Vol. 16 Issue 3, p269 

    This paper reviews the results of randomized clinical trials of psychological and/or pharmacological treatments for smokers. Special attention has been devoted to subjects with or without a history of depressive disorder. A 6 to 12 months biochemically validated abstinence was used as main...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics